China Amino Acid Suppliers
Here you can find the related products in Amino Acid, we are professional manufacturer of Amino acid. We focused on international export product development, production and sales. We have improved quality control processes of amino acid to ensure each export qualified product.
If you want to know more about the products in Amino Acid, please click the Product details to view parameters, models, pictures, prices and Other information about Amino Acid.
Whatever you are a group or individual, we will do our best to provide you with accurate and comprehensive message about Amino Acid!
BCAA,L-Serine, L-arginine,L-Citrulline,L-Lysine, glycine,Amino Acids Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualyn-bio.com
China's first HIV treatment single-chip combination preparation
Recently, GlaxoSmithKline (GSK) announced that its holding joint venture, ViiV Healthcare1, is a single-chip compound preparation with a new generation of integrase inhibitor, dobutavir, as a core ingredient. Listed in mainland China, this is also the first complete combination of the first complete treatment plan in the field of HIV treatment in China, which will make HIV treatment more convenient and efficient.
Fighting AIDS should be treated as soon as possible and adhered to treatment
The data show that as of the end of October 2017, China reported a total of 746,000 cases of HIV-infected and AIDS patients, and reported 229,000 deaths. The number of people receiving antiretroviral treatment at the end of 2016 was 495,000.
On January 19, 2017, the General Office of the State Council issued the "13th Five-Year Plan of Action for Containment and Prevention of AIDS in China", stating that it is necessary to achieve "more than 90% of infected people and patients diagnosed and aware of their infection status", "The proportion of infected patients and patients who meet the treatment conditions is more than 90%", and the "three 90%" prevention and treatment goals of "infected patients and patients receiving antiviral treatment have a success rate of more than 90%".
"To achieve the 'three 90%' goals at an early date, doctors, enterprises , governments, social organizations and other parties need to work together. Among them, it is the responsibility of doctors to choose the right drugs for infected people and patients to help them treat them as soon as possible and adhere to treatment. Professor Wu Wei, director of the Infection Center of You'an Hospital affiliated to Capital Medical University, said that early anti-viral treatment by infected people can not only control the deterioration of the disease, but also reduce the chance of transmitting the virus to others. "Ideal antiviral drugs should be highly effective, well tolerated, have high drug resistance barriers, low adverse events, easy to take, and less interaction with other drugs. More than abalone tablets as a complete treatment option. Single-chip combination preparation, taken once a day, without considering the food effect, can reduce the burden of medication, improve treatment compliance, and improve the quality of life of infected people."
According to Professor Zhang Fuji, director of the Center for Infectious Clinical and Research Centers at Beijing Ditan Hospital, Capital Medical University, the launch of new drugs is a major step forward in China's existing antiviral treatment. "Currently, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose combination preparations have become the trend of future treatment." Zhang Fujie said.
It is reported that the newly listed drug is a three-in-one compound drug with dotivide (DTG) as the core. It has been approved for marketing in 50 countries and regions, and has been recommended as the initial treatment by many authoritative academic institutions and authoritative guidelines in Europe and America. The first-line treatment for HIV-infected patients.
AIDS drug development to promote innovation
As a global pharmaceutical and healthcare company, GSK began to bring innovative treatment options for HIV-infected persons from China since 1999. In 2017, the new drug for treatment of HIV, Dobrinide, was launched in China.
“Improving the accessibility of innovative medicines is a clear strategy for us to implement our commitment to 'based on China, join hands with China, and serve China.'†Wei Liansheng, general manager of GSK China's prescription drugs and vaccines department, said, “We are working with a number of organizations to carry out HIV/AIDS health care personnel training, as well as disease prevention and education programs, so that people living with HIV can get better support and help."
According to Dr. Xu Ding, Vice President of GSK Government Affairs and Communications, since 2016, GSK has teamed up with the Chinese Preventive Medicine Association (CPMA) to work together on the development of a talent team in the field of AIDS medicine, as well as AIDS prevention and education programs. GSK also sponsored a charity organization, Beijing Red Ribbon House, to carry out a series of project activities focusing on professional training and disease advocacy, and invested millions of dollars to support the "Red Ribbon Health Ambassador Youth Campus" campaign, aiming through a series of publicity and education. Activities have enabled the whole society, especially young students, to further understand the importance of AIDS prevention and control efforts and curb the AIDS epidemic.
“In 2016, GSK established the Institute of Infectious Diseases and Public Health in Beijing and signed a memorandum of strategic cooperation with Tsinghua University. The Institute is responsible for leading the development of innovative infectious disease drugs in China, including HIV prevention and prevention. In the future, there will be more innovative drugs in the field of HIV treatment being introduced into the Chinese market.†Xu Ding said, “AIDS is a major public health problem for China and the world, and the disease field is also GSK. One of the key global research and development strategies. We are committed to continuous research and development of innovative drugs, breaking through existing treatment programs, promoting the development of prevention and treatment in the AIDS field, and continuously introducing innovative AIDS treatments to China."